ATYR1923-C-005_SSc-ILD_EFZO-CONNECT (Systemic Sclerosis-Related Interstitial Lung Disease) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called efzofitimod (the study drug) is a safe and effective option for people with SSc-ILD. We want to know how well the study drug works against the skin and lung effects caused by SSc-ILD.
Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with SSc-ILD
- Have been taking mycophenolate mofetil (MMF) for at list 6 months, or if not on MMF,
taking a different immunosuppressant for SSc-ILD - Have lung disease caused by scleroderma (i.e. ILD), confirmed by high-resolution
computed tomography (HRCT)
For more information, contact the study team at wendy.curry@duke.edu.
What is Involved?
If you choose to join this study, you will get a random assignment (fair chance) to either take the study drug or a placebo (inactive substance that has no drug in it). You will have a 4-in-5 chance of taking the study drug and a 1-in-5 chance of taking a placebo.
You will visit our clinic 9 times while you take part in the study. During these visits, you will have physical exams, breathing tests, and skin biopsies (2 visits only - at the beginning of the study and after 3 months of taking the study drug/placebo).
Study Details
